🇺🇸 Fraxiparine in United States
539 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 28 March 2025 – 28 March 2026
- Total reports: 539
Most-reported reactions
- Thrombocytopenia — 64 reports (11.87%)
- Pyrexia — 60 reports (11.13%)
- Drug Interaction — 59 reports (10.95%)
- Pulmonary Embolism — 59 reports (10.95%)
- Pneumonia — 55 reports (10.2%)
- Dyspnoea — 52 reports (9.65%)
- Fall — 50 reports (9.28%)
- Hypotension — 48 reports (8.91%)
- Dehydration — 46 reports (8.53%)
- Diarrhoea — 46 reports (8.53%)
Other Cardiovascular approved in United States
Frequently asked questions
Is Fraxiparine approved in United States?
Fraxiparine does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for Fraxiparine in United States?
Leiden University Medical Center is the originator. The local marketing authorisation holder may differ — check the official source linked above.